General Information of DTT (ID: TTCI43M)

DTT Name GABA(A) receptor (GABAR) DTT Info
Gene Name GABAR

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ganaxolone DMXJMKF Epileptic seizures 8A61-8A6Z Approved [1]
------------------------------------------------------------------------------------
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
OV101 DMA6LR3 Angelman syndrome LD90.0 Phase 3 [2]
PH94B NS DMDC7OH Social anxiety disorder 6B04 Phase 3 [3]
Padsevonil DMRZ1F2 Epilepsy 8A60-8A68 Phase 2/3 [4]
BTD-001 DMS6ZA0 Narcolepsy 7A20 Phase 2 [5]
Evt201 DM8QXEY Sleep-wake disorder 7A00-7B2Z Phase 2 [6]
SAGE-324 DM5NC39 Essential tremor or related tremors 8A04.1 Phase 2 [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
Molecule Interaction Atlas

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215904.
2 Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.
7 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.